Chemistry:EVT-103
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Other names | ENS-103 |
| Routes of administration | By mouth |
| Drug class | NMDA receptor antagonist |
| Identifiers | |
| CAS Number | |
EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist.[1] As of November 2017, no recent reports of development for major depressive disorder have been identified.[1] The drug was developed as a follow-up compound to EVT-101.[2] The chemical structure of EVT-103 has not been released.[2]
See also
References
- ↑ 1.0 1.1 1.2 "EVT 103". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800030864.
- ↑ 2.0 2.1 "NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments". Annual Reports in Medicinal Chemistry Volume 47. 47. 2012. pp. 89–103. doi:10.1016/B978-0-12-396492-2.00007-2. ISBN 9780123964922.
 |  |
